Back to results
US 2024/0252473 A1Published application
Sulfoximines as inhibitors of NaV1.8
AssigneeGruenenthal GmbH
InventorsMarcel MUELBAIER, Sebastian KRUEGER, Clemens DIALER, Mauro MARIGO, Vipulkumar PATEL
Life of this patent
Estimating the term…
Abstract
Compounds according to general formula (I) act as inhibitors of NaV1.8 and can be used in the treatment of pain.
Claims22
A compound according to formula (I):
- wherein
- one of A1, A2 and A3 represents C—R3 and another two of A1, A2 and A3 independently from one another represent CR′ or N;
- R′ independently represents H, F, CH3, CH2F, CHF2, CF3, or OCH3;
- L represents CH2, CH(CH3) or CH(CH2CH3);
- R1 represents C3-10-cycloalkyl, 4 to 11-membered bicycloalkyl, 5 to 11-membered spiroalkyl or dispiroalkyl, 4 to 10-membered heterocycloalkyl, or 5 to 11-membered heterobicycloalkyl;
- R2 represents H or C1-6-alkyl;
- R3 represents S(O)(NR3a)R3b or S(NR3a)2R3b;
- R3a represents H, C1-6-alkyl, C(O)C1-5-alkyl, C(O)C1-5-alkyl-NH2, C(O)C1-5-alkyl-NH—CH3, C(O)C1-5-alkyl-N(CH3)2, C3-10-cycloalkyl, C1-6-alkylene-C3-10-cycloalkyl, 4 to 10-membered heterocycloalkyl, or C1-6-alkylene-(4 to 10-membered heterocycloalkyl);
- R3b represents NH2, C1-6-alkyl, C3-10-cycloalkyl, C1-6-alkylene-C3-10-cycloalkyl, 4 to 10-membered heterocycloalkyl, or C1-6-alkylene-(4 to 10-membered heterocycloalkyl);
- or R3a and R3b mean (CH2)3-5 and together with the atoms to which they are attached form a ring;
- R4 represents H, F, Cl, Br, CN, CHF2, CH2F, CF3, C1-6-alkyl, C3-10-cycloalkyl, C1-6-alkylene-C3-10-cycloalkyl, 4 to 11-membered bicycloalkyl, 5 to 11-membered spiroalkyl or bisspiroalkyl, 4 to 10-membered heterocycloalkyl, C1-6-alkylene-(4 to 10-membered heterocycloalkyl), NH2, N(H)(C1-6-alkyl), N(C1-6-alkyl)2, O—C1-6-alkyl, O—C3-10-cycloalkyl, O—C1-6-alkylene-C3-10-cycloalkyl, O-(4 to 6-membered heterocycloalkyl), or O—C1-6-alkylene-(4 to 6-membered heterocycloalkyl);
- R5 represents H, F, Cl, Br, CN, CHF2, CH2F, CF3, C1-6-alkyl, C3-10-cycloalkyl, C1-6-alkylene-C3-10-cycloalkyl, 4 to 10-membered heterocycloalkyl, C1-6-alkylene-(4 to 10-membered heterocycloalkyl), NH2, N(H)(C1-6-alkyl), N(C1-6-alkyl)2, O—C1-6-alkyl, O—C3-10-cycloalkyl, O—C1-6-alkylene-C3-10-cycloalkyl, O-(4 to 6-membered heterocycloalkyl), or O—C1-6-alkylene-(4 to 6-membered heterocycloalkyl);
- wherein C1-6-alkyl and C1-6-alkylene in each case independently from one another is linear or branched;
- wherein C1-6-alkyl, C1-6-alkylene, C3-10-cycloalkyl, C3-6-cycloalkyl, 4 to 11-membered bicycloalkyl, 5 to 11-membered spiroalkyl or dispiroalkyl, 4 to 10-membered heterocycloalkyl, 4 to 6-membered heterocycloalkyl, and 5 to 11-membered heterobicycloalkyl in each case independently from one another are unsubstituted or substituted with one, two, three, four or more substituents independently from one another selected from the group consisting of F, Cl, CN, C1-6-alkyl, C1-6-alkylene-OH, C1-6-alkylene-OCH3, CF3, CF2H, CFH2, C(O)—C1-6-alkyl, OH, ═O, OCF3, OCF2H, OCFH2, O—C1-6-alkyl, C1-4-alkylene-O—C1-4-alkylene-O—CH3, C0-4-alkylene-O—(C1-4-alkylene-O)1-4—CH3, NH2, NH—C1-6-alkyl, N(C1-6-alkyl)2, or 4 to 6-membered heterocycloalkyl;
- in the form of a free compound or a physiologically acceptable salt thereof.
12 more elements
Dependencies are inferred from the claim text.